Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Itabajara da Silva Vaz Junior
 -- 4397 2023-06-30 19:51:06 |
2 layout
Camila Xu
 Meta information modification 4397 2023-07-03 03:28:02 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Parizi, L.F.; Githaka, N.W.; Logullo, C.; Zhou, J.; Onuma, M.; Termignoni, C.; Da Silva Vaz, I. Universal Tick Vaccines. Encyclopedia. Available online: https://encyclopedia.pub/entry/46286 (accessed on 19 May 2024).
Parizi LF, Githaka NW, Logullo C, Zhou J, Onuma M, Termignoni C, et al. Universal Tick Vaccines. Encyclopedia. Available at: https://encyclopedia.pub/entry/46286. Accessed May 19, 2024.
Parizi, Luís Fernando, Naftaly Wang’ombe Githaka, Carlos Logullo, Jinlin Zhou, Misao Onuma, Carlos Termignoni, Itabajara Da Silva Vaz. "Universal Tick Vaccines" Encyclopedia, https://encyclopedia.pub/entry/46286 (accessed May 19, 2024).
Parizi, L.F., Githaka, N.W., Logullo, C., Zhou, J., Onuma, M., Termignoni, C., & Da Silva Vaz, I. (2023, June 30). Universal Tick Vaccines. In Encyclopedia. https://encyclopedia.pub/entry/46286
Parizi, Luís Fernando, et al. "Universal Tick Vaccines." Encyclopedia. Web. 30 June, 2023.
Universal Tick Vaccines
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ani13122031

Vaccination is usually proposed as a safe and sustainable strategy to overcome problems related to tick infestation and disease transmission. However, progress in anti-vector vaccine development has been slow and patchy, and currently, only a handful of vaccines targeting ectoparasites have been developed and tested successfully.

cross-protection parasite tick tick-control vaccine

1. Introduction

Veterinary ectoparasites, such as ticks, cause enormous economic losses, both directly through bloodsucking and irritation that affect animal welfare, and indirectly through the transmission of often debilitating diseases such as babesiosis, theileriosis, and anaplasmosis [1]. Besides the high cost of currently available control methods, the increasing resistance to the drugs used to control vector infestation and treatment for tick-borne diseases is a major concern worldwide [2]. To enhance the introduction of new animal health products into specific markets, such as sub-Saharan Africa or South America, it is crucial to implement innovative strategies in product development that target the diseases endemic in these regions [3].
Vaccination is usually proposed as a safe and sustainable strategy to overcome problems related to tick infestation and disease transmission. However, progress in anti-vector vaccine development has been slow and patchy, and currently, only a handful of vaccines targeting ectoparasites have been developed and tested successfully [4][5]. Moreover, the commercialization of promising vaccine candidates for livestock disease is still a complicated process despite lower regulatory thresholds compared to human vaccines [6][7]. Regarding vector-borne diseases endemic in low-income countries, it is difficult to recoup investments in vaccine development in the absence of government support [8].
The evolutionary complexity of parasites and their intimate relationships with their vertebrate hosts pose a daunting challenge to rationally design vaccines against these organisms [9]. All of them can trigger host innate and adaptive immunity that is often stage-specific [10]. However, parasites (including ticks) possess potent defense mechanisms to overcome or circumvent host immune responses, thus re-establishing the balance in favor of the parasite [11][12][13][14][15][16][17]. Tick-host interactions over the past 100 million years resulted in the coevolution of an enormous range of proteins and non-protein factors secreted in tick saliva. These factors are used initially to locate their hosts and feeding sites and subsequently to inhibit or modulate the host defense [18], including the hemostatic and immune system [19][20][21].
On the other hand, some host species promptly develop protective immune responses that reject ticks. Therefore, understanding the mechanisms that trigger this protection is crucial in order to gain a better understanding of tick-host interaction and to find molecular targets for a vaccine [22]. In some cases, hosts are able to develop a boosting protection after a second tick infestation [23]. However, due to economic and health reasons, it is not feasible to rely on the development of natural immunity in order to achieve a reasonable level of protection for humans and animals against ticks. Moreover, since ticks are vectors of many important pathogens [24], it is critical to develop a preventive protection method before the onset of parasitism [25].
Universal vaccines against ticks, i.e., vaccines able to protect against different tick species, could reduce the costs of control programs. This is because hosts infested by two or more tick species in one area could be protected using a single vaccine [26]. This advantage encouraged many research groups worldwide to analyze tick proteins that were originally used as antigens for homologous vaccination [27] in trials against several tick species. Previously, several tick proteins were suggested as candidates for a universal vaccine [28][29].

2. Previously Described Universal Vaccine Antigen Candidates

2.1. Bm86

Bm86 protein is a Rhipicephalus (Boophilus) microplus (Canestrini, 1888) structural gut glycoprotein that was identified after a series of sequential fractionations of tick proteins, which were used to protect bovines against tick infestations [30][31]. This research was seminal because it introduced the concept of concealed antigen, defined as an antigen that is not encountered by the host immune system under natural conditions but can be reached by host antibodies in the case the host was previously immunized with this molecule. Recombinant proteins based on R. (B.) microplus Bm86 are the only antigens used in commercially developed anti-tick vaccines ever developed, named TickGard [32] and Gavac [33]. Nowadays, however, only Gavac is commercially available in some regions [34]. It has a 55–100% efficacy against R. (B.) microplus populations in Latin America [35]. Since Bm86 discovery in the 1980s, huge efforts were undertaken to find protective antigens to be included in universal vaccines [29]. Preliminary results showed that Bm86 and other tick proteins induce partial cross-protection levels, leading many research groups to perform vaccination trials testing putative universal antigens. Table 1 summarizes such trials in recent years.
Table 1. Vaccination trials showing cross-protective vaccine efficacies using tick antigen candidates.
Name Target Tick Species Cross-Protected Tick Species/Host Vaccine Efficacy/Infestation Stage References
Bm86 and orthologs R. (B.) microplus Hyalomma anatolicum anatolicum (Koch, 1844)/cattle 36.5% (L) [36]
  H. a. anatolicum R. (B.) microplus/cattle 26.8% (L); 25.1% (AF) [36]
  R. (B.) microplus Hyalomma dromedarii (Koch, 1844)/cattle 89% a, 98% a (L); 29% a, 36% a (AF) [26]
  R. (B.) microplus H. dromedarii/camel 26.7% a, 31.3% a 38.6% a (AF) [26]
Subolesin and orthologs Ornithodoros erraticus (Lucas, 1849) d Ornithodoros moubata (Murray, 1877)/rabbit ~40.0% (L, N, AF) [37]
  O. moubatad O. erraticus/rabbit 50.3% (L, N, AF) [37]
  H. a. anatolicum R. (B.) microplus/cattle 54% (L) [38]
  Rhipicephalus appendiculatus (Neumann, 1901) Amblyomma variegatum (Fabricius, 1794)/cattle b 50% and 89% (L) [39]
  R. appendiculatus Rhipicephalus (Boophilus) decoloratus (Koch, 1844)/cattle c 51% (L) [39]
  A. variegatum R. appendiculatus/cattle b 86% and 83% (L) [39]
  A. variegatum R. (B.) decoloratus/cattle c 72% (L) [39]
  R. (B.) decoloratus R. appendiculatus/cattle b 66% and 89% (L) [39]
  R. (B.) decoloratus A. variegatum/cattle b 58% and 94% (L) [39]
  Rhipicephalus haemaphysaloides (Supino, 1897) Haemaphysalis longicornis (Neumann, 1901) 79.3% and 86.6% (AF) [40]
  R. (B.) decoloratus R. appendiculatus/cattle 99% (L, N, AF) [41]
Calreticulin H. a. anatolicum R. (B.) microplus/cattle 37.56% (L) [38]
CathL H. a. anatolicum R. (B.) microplus/cattle 22.21% (L) [38]
GST H. longicornis R. appendiculatus/rabbit 67% (AF) [42]
  R. (B.) decoloratus/A. variegatum e Rhipicephalus sanguineus s.l. (Latreille, 1806)/rabbit 35% (AF) [43]
P0 R. sanguineus s.l./R. (B.) microplus d R. (B.) microplus/cattle 96% (L) [44]
  R. sanguineus s.l./R. (B.) microplus d Amblyomma mixtum (Koch, 1844)/rabbit 54% (L) [45]
Aquaporin R. (B.) microplus R. sanguineus s.l./dog 7.2% (L); 4.5% (N) [46]
  O. erraticus O. moubata/rabbit 9.3% (AF) [47]
ABC transporter O. erraticus O. moubata/rabbit 26.7% (AF); 15.4% (AM) [47]
Selenoprotein T O. erraticus O. moubata/rabbit 18.6% (AM) [47]
Ferritin Ixodes persulcatus (Schulze, 1930) Ixodes ovatus (Neumann, 1899)/guinea pig ~40% (AF) [48]
Cystatin R. (B.) microplus R. appendiculatus/rabbit 11.5% (AF) [49]
Chitinase O. erraticus O. moubata/rabbit 19.6% (AF) [50]
Secreted protein PK-4 O. erraticus O. moubata/rabbit 8.1% (N, AM) [50]
OM03, OM85 and OM99 peptides O. moubata O. erraticus/rabbit 20.7% to 66.1% (N, AF, AM) [51]
CathL, cathepsin L-like cysteine proteinase; GST, glutathione S-transferase; P0, 60S acidic ribosomal protein. L, larva; N, nymph; AF, adult female; AM, adult male. a protection for specific parameters. b For Bos indicus (Linnaeus, 1758) and B. indicus × Bos taurus (Linnaeus, 1758) breeds, respectively. c B. indicus × B. taurus breed. d peptide conjugates. e cocktail vaccine.
Previously, an overall 50% reduction in the engorgement weight of H. a. anatolicum nymphs fed on Bm86-vaccinated calves was obtained [52]. Furthermore, Bm86 and its orthologue Haa86 from H. a. anatolicum were used in a vaccination trial against R. (B.) microplus and H. a. anatolicum infestations [53]. Although both Bm86 and Haa86 presented cross-protection, these antigens showed a higher species-specific efficacy, similar to other H. a. anatolicum subolesin, calreticulin, and cathepsin L-like cysteine proteinase antigens [38]. Additionally, Bm86 was effective against H. dromedarii infestations in cattle and camels. On the other hand, the same antigen failed to protect cattle against Amblyomma sculptum (Berlese, 1888) [26]. In another cross-vaccination trial against Hyalomma spp., Hd86 (Hyalomma scupense (Schulze, 1919) Bm86 orthologue), immunized calves presented a decrease in the number of H. scupense larva, an effect not observed in calves that were immunized with Bm86 [54]. Intriguingly, Hd86 and Bm86 immunization increased H. scupense and Hyalomma excavatum (Koch, 1844) adult female weight, respectively, showing that Hd86 and Bm86 efficacy varies according to the tick life stage. It was suggested that Hd86 and Bm86 protection rates variation could result from differences in amino acid sequences of these antigens among tick species [55] and tick populations [56], as well as different levels of protein expression in immature and adult life stages [57].
Distinct Bm86 vaccine efficacies against Rhipicephalus (Boophilus) annulatus (Say, 1821) and R. (B.) microplus could also be related to the activity of tick endogenous protein degradation machinery (proteases) [58]. Since Bm86 protein expression levels in both tick species are similar, distinct physiologic factors could have caused an increased R. (B.) annulatus susceptibility to Bm86 vaccine. Proteomic analysis showed R. (B.) annulatus has reduced protein degradation machinery compared to R. (B.) microplus, which leads to a higher susceptibility to host immune response factors such as antibodies and the complement system [58]. It was proposed that Bm86 could be useful in controlling R. (B.) annulatus and R. (B.) microplus in endemic regions, e.g., North America, using vaccination and standard eradication practices simultaneously [59][60].

2.2. Subolesin

Subolesin and their orthologs (akirins) are transcription factors that regulate the expression of signal transduction and innate immune response genes in ticks and other parasites [61][62][63][64]. Cross-protection experiments showed high vaccine efficacies using subolesin and akirins against different parasite species, making these antigens very promising for a broad universal vaccine [29]. These trials supported further investigations analyzing the efficacy of subolesin antigens against different parasite and host species using alternative vaccination protocols. Mono- and multi-antigenic formulations of R. appendiculatus, R. (B.) decoloratus and A. variegatum subolesins were used in B. indicus and B. indicus × B. taurus crossbred cattle, with an efficacy range of 47–94% [39]. However, the protection developed by bovines immunized with this multi-antigenic formulation was not improved when compared to mono-antigenic formulations. A different vaccine strategy, using an oral vaccine combining R. (B.) decoloratus subolesin and heat-inactivated Mycobacterium bovis, induced protection against an R. (B.) decoloratus and R. appendiculatus infestation in B. indicus × B. taurus crossbred cattle [41].
In light of evidence showing that subolesin and akirin induce partial protection against Hyalomma spp. and Rhipicephalus spp. infestations in red and white-tailed deer [65], field vaccination trials were performed using roe deer, another cervid that is highly important as a host for ticks and tick-borne pathogens in Europe [66]. For this trial, a chimera of Ixodes scapularis (Say, 1821) subolesin and Aedes albopictus (Skuse, 1894) mosquito akirin (Q38) was used, since its protective epitopes are conserved among distinct parasites [67], which is a necessary feature for a universal vaccine. Although the tick species collected in the field were not definitely identified, the roe deer showed a smaller number of ticks (likely Hyalomma marginatum (Koch, 1844), Hyalomma lusitanicum (Koch, 1844), Rhipicephalus bursa (Canestrini and Fanzago, 1878), and Ixodes ricinus (Linnaeus, 1758) compared with non-vaccinated animals. Noteworthy, Q38 was able to induce immune protection in rabbits against larvae of I. ricinus and Dermacentor reticulatus (Fabricius, 1794) [68], showing Q38’s potential to protect against different tick life stages.
Vaccinations trials using subolesin against the soft ticks O. erraticus and O. moubata showed a low degree of protection [69], probably due to the induction of non-protective antibodies for immunodominant subolesin epitopes in highly structured regions [37]. Subsequently, the prediction of subolesin linear B-cell epitopes, using peptide arrays, epitope mapping (pepscan), and modelling, was used to design synthetic peptides that increased the protection rates against these ticks [37]. Besides the use of the complete protein as an antigen, immunization with synthetic subolesin peptides stimulated the host immune system to develop antibodies against subolesin unstructured regions. Therefore, the prediction of B-cell and T-cell epitopes represents a promising tool to improve the immunogenicity of other tick antigen candidates that show low degree of protection [70], as well as to design chimeras containing subolesin or other protective antigenic epitopes [71]. Recently, an antigenic B-cell epitope peptide from subolesin was tested as a potential vaccine candidate using artificial capillary feeding experiments [72] and vaccination under stable [73] and field [74] conditions, showing partial protection against tick infestation.
Moreover, an alternative approach using a priming immunization with a DNA vaccine expressing R. haemaphysaloides subolesin, followed by boosters of R. haemaphysaloides recombinant subolesin or R. haemaphysaloides subolesin and H. longicornis P0 chimeric polypeptide provided cross-protection against H. longicornis of 79% and 86%, respectively [40]. The combination of a DNA vaccine with mono- or multi-protein immunizations is a promising strategy to increase the efficacy of anti-tick vaccines.

2.3. Glutathione S-Transferases

Glutathione S-transferases (GSTs) are enzymes involved in the detoxification of xenobiotics and endogenous compounds [75]. The potential of H. longicornis GST (GST-Hl) to protect bovines against R. (B.) microplus parasitism has been analyzed [76]. A vaccination trial showed that GST-Hl combined with R. (B.) microplus Vitellin-Degrading Cysteine Endopeptidase and Boophilus Yolk pro-Cathepsin decreased R. (B.) microplus infestation in cattle, conferring an overall protection ranging from 35% to 61% for 3 months [76]. Moreover, R. appendiculatus adult females fed on rabbits immunized with GST-Hl are negatively affected, leading to an overall vaccine efficacy of 67% [42]. However, the same antigen was ineffective in protecting rabbits against R. sanguineus s.l. [42]. Furthermore, immunogenicity and cross-recognition of GSTs from R. appendiculatus, R. (B.) decoloratus, R. (B.) microplus, A. variegatum, and H. longicornis were analyzed [43]. Rhipicephalus (B.) decoloratus and A. variegatum GST presented high cross-protection potential and were selected to compose an experimental cocktail vaccine, which was able to reduce 35% of R. sanguineus s.l. adult female numbers in immunized rabbit. All together, these data demonstrate that GSTs are potentially useful antigens to compose vaccines against Rhipicephalus spp.

3. New Cross-Protection Antigen Candidates

Protein P0, one of the eukaryotic 60S ribosomal proteins, has a high identity among ticks of different genera but a low sequence similarity with their hosts’ P0 [77], which is an important feature for candidate antigens. Rhipicephalus sanguineus s.l. and R. (B.) microplus P0 have identical sequences, from which a peptide composed of 20 amino acids within a highly immunogenic region was synthetized and used in vaccination trials [77]. The overall efficacy of this peptide as a protective antigen was 90% for R. sanguineus s.l. [77] and 54% for A. mixtum [45] in rabbits, and 96% against R. (B.) microplus in cattle [44]. Surprisingly, when the same peptide was tested as a conjugate with Bm86 to immunize dogs and cattle, the efficacies were 95% (peptide alone) and 85% (conjugated) against R. sanguineus s.l., and 89% (peptide alone) and 84% (conjugated) against R. (B.) microplus [78], indicating that the effect is not additive. However, O. erraticus P0 showed no cross-protection against O. moubata infestation [50]. Thus, the antigen P0 may be useful to compose a broad-spectrum vaccine against hard ticks, as well as against pathogens transmitted during tick feeding, as demonstrated for Babesia spp. [79].
Using a vaccinomic approach, new tick proteins with high efficacy in controlling I. ricinus and D. reticulatus in rabbits and dogs [80] were successfully identified. These trials showed efficacies up to 80% in animals individually inoculated with the following proteins: (1) heme lipoprotein from I. ricinus, (2) glypican-like protein, (3) secreted protein involved in homophilic cell adhesion, (4) sulfate/anion exchanger, or (5) signal peptidase complex subunit 3 from D. reticulatus. Similarly, through omics and in silico prediction algorithms, peptides from O. moubata midgut membrane antigens were selected for rabbit vaccination against O. moubata and O. erraticus [51]. Interestingly, the levels of protection were higher against O. erraticus than O. moubata. Other proteins in the Ixodidae and Argasidae families, such as R. (B.) microplus [46] and O. erraticus [47] aquaporins, O. erraticus ABC transporter, selenoproteins T, chitinase, secreted protein PK-4 [47][50], Ixodes persulcatus ferritin 2 [48] and R. (B.) microplus cystatins [49], showed limited cross-protection rates. Further studies are necessary to improve the protection levels achieved with these antigens.

4. Vaccines Blocking Pathogen Transmission

An alternative strategy to control tick-borne pathogens is through a vaccine that can block the transmission of these organisms to the host [81]. Some pathogens take advantage of tick saliva molecules for their transmission at an early stage of tick attachment, which increases their dissemination to the host [82]. If a vaccine is able to interfere in key tick physiology processes, pathogen transmission could be blocked. Examples of such processes and potential antigens include: (1) disruption of tick defense mechanisms targeting the microbiota biofilm modulator PIXR [83], (2) reduction in tick attachment time on the host by targeting the cement cone protein 64TRP [84][85], and (3) impairment of tick molecules that favor pathogen development and invasion into the tick, such as the antimicrobial protein IAFGP [86]. In this sense, a proposal for a universal anti-tick vaccine with a transmission-blocking potential is a promising tool to control ticks and pathogens, as suggested for Bm86 homologues to control Borrelia burgdorferi (Burgdorfer, 1982) host infection [87].
Another example of a candidate antigen to control pathogens includes a R. (B.) microplus subolesin fused with Anaplasma marginale (Theiler, 1910) Major Surface Protein 1a (SUB-MSP1a), which showed cross-protection potential against R. (B.) annulatus [88]. SUB-MSP1a was further used in bovine and sheep vaccination trials against R. (B.) microplus [89]. In this trial, the prevalence of Babesia bigemina (Wenyon, 1926) was reduced, showing the potential of SUB-MSP1a to control tick infestations and pathogen infection/transmission. Indeed, subolesin was also shown to be important for tick transmission of Anaplasma phagocytophilum (Foggie 1949), A. marginale, and B. burgdorferi [90]. Nevertheless, the multi-antigenic vaccine containing R. (B.) microplus subolesin, R. appendiculatus TRP64, and 3 histamine binding proteins, as well as Theileria parva (Theiler, 1904) sporozoite antigen p67C, did not affect R. appendiculatus survival and transmission of T. parva to cattle [91]. Using a different methodology, I. ricinus fed by artificial membranes with blood containing antibodies against an I. scapularis lipocalin or against an I. scapularis lectin, impaired tick engorgement, as well as A. phagocytophilum infection [92]. These two antigens identified using a vaccinomic approach are good examples of how this methodology can be useful for antigen discovery.
In addition to that, a live anti-tick vaccine was developed using attenuated Babesia bovis as a carrier to express tick proteins in calves [93]. The calves immunized with B. bovis carrying the H. longicornis GST gene generated anti-HlGST antibodies and developed mild babesiosis. Rhipicephalus (B.) microplus reared in these calves were smaller, and their fecundity was affected. This dual vaccine approach opens the perspective to develop universal vaccines not only against several tick species but also against tick-borne pathogens.

5. Advances and Remaining Challenges to Universal Tick Vaccines

This essay reviews studies showing tick antigens being evaluated for vaccine protection levels, including different stages of method development: from in silico or in vitro antigenicity, antibody cross-binding, and artificial feeding analysis, to vaccination trials using target hosts such as cattle, deer, and dogs. However, it is difficult at this point to compare them directly in order to find the best options to be included in a multi-antigenic vaccine. Even when limiting the comparison to antigens that were already analyzed in natural hosts, there are many biological variables to consider in differentiating vaccine efficacies, including host and tick diversity [39][94][95]. Moreover, although Canales’ method [33] for calculating the overall efficacy of the vaccine has become a standard and has been widely used in vaccination trials, alternative considerations have also been employed to evaluate levels of vaccine protection. These differences make it challenging to compare the level of protection across different studies [96][97]. The use of standard protocols would be helpful to allow the estimation of vaccine efficacy for ticks with similar biology and for similar experimental approaches.
Another important point in cross-vaccination studies is to verify if a given tick species is not actually two or more related but distinct species. Accurate species identification is fundamental to analyze homologous or heterologous vaccine efficacies [98]. Some examples of ticks that were the subject of vaccination trials and were under-speciated groups at the time include: (1) the formerly Amblyomma cajenense (Fabricius, 1787), now known as a complex of six valid species, including A. sculptum [99], (2) R. sanguineus s.l., which is contested to comprise multiple distinct species [100], and (3) R. (B.) microplus, which was also split into two species, giving rise to the new species Rhipicephalus (Boophilus) australis (Fuller, 1899) [101]. Thus, for example, vaccine antigen candidates such as protease inhibitors used against A. sculptum [102] must be considered as heterologous protection against other A. cajennense complex species. Importantly, the low protection rates obtained in some vaccination trials performed on R. (B.) microplus using TickGard and R. australis using Gavac could be the result of physiologic and/or Bm86 amino acid sequence variations between these two species [36][103][104]. Nevertheless, the selection of vaccine antigens from conserved proteins among tick species or isolates from different geographic areas will contribute to avoid vaccine inefficacy due to tick species misidentification [105][106]. In this context, the development of universal vaccines is highly desirable.

5.1. Rational Strategies for Improving Tick Vaccines

Different protocols for improving vaccines against multiple tick species were developed recently, thanks to advances in molecular biology, bioinformatics, and new material for vaccine components, such as adjuvants. Furthermore, the use of multiple antigens in a universal vaccine has been proposed, offering advantages such as protection against different tick species and different stages of the tick life cycle, in addition to the pathogens carried by them [107]. Multi-antigenic vaccines prove particularly advantageous for ticks with a single host, such as R. (B.) microplus, as they remain on the same host throughout their larval, nymphal, and adult stages. During this parasitic cycle, the tick produces distinct molecules to evade the host’s immune response [108][109][110][111]. Moreover, for multi-antigenic vaccines to be effective against ticks with three hosts, they must incorporate proteins specific to each life stage of the parasite that infests each host. Therefore, regardless of the number of hosts affected by tick infestations, a multi-antigenic vaccine should encompass protective antigens targeting various life stages of different tick species, as well as different secreted molecules by the same tick species. The use of multiple antigens in single vaccines or chimeric constructs has shown promising levels of protection in some cases, although some antigen combinations did not increase vaccine efficacy [107]. An interesting strategy proposed was the use of oral vaccines for the control of tick infestations, which, despite being incipient, affected tick survival and fertility, justifying further experiments [41][112].
In addition to in vivo trials, the immunogenicity of a number of tick molecules was analyzed in silico, revealing the potential of cross-protective tick antigens to be used for other tick species, such as aquaporin [113] and GSTs [114]. Similarly, potential proteins to be used for vaccines were discovered by reverse vaccinology analysis [97][115]. The use of systems biology is also a promising technique for the development of vaccines against ticks and their vectored pathogens [116]. Using this tool, it is possible to propose antigens for new generation vaccines that make use of transcriptomes, proteomes, and immunogenomics. Through “omics” analyses, it is possible to find not only antigens but also adjuvants for use in tick vaccines [107]. New generation adjuvants are under development to increase the immune response level, quality, and duration against infection and parasitic diseases [117][118]. For ticks, the performance of adjuvant formulations is currently being analyzed to improve the efficacy of known antigens such as Bm86, showing increased protections levels, although adverse reactions such as cutaneous side effects remain an issue [119]. A self-adjuvancing antigen carrier study indicated the immunogenicity, biodistribution, and safety of Bm86 carried by silica nanoparticles, demonstrating the potential of this delivery platform in anti-tick vaccine applications [120].
New vaccine delivery systems are being developed to protect against ticks and tick-borne diseases, including the use of lipid nanoparticle (LNP)-mRNA vaccines [121][122]. This technology offers an alternative to live attenuated or subunit-based vaccines [123]. An Ixodes scapularis salivary gland protein encoded by mRNA using this system decreased tick engorgement and B. burgdorferi transmission [122]. Interestingly, immunization with mRNA encapsulated into lipid nanoparticles induced not only a humoral immune response against Powassan virus, another pathogen transmitted by I. scapularis, but also against other tick-borne flaviviruses [121]. Other promising delivery systems include viral vectors [124] and live parasite vaccines [125].

5.2. Impact of Tick Expansion into New Territories for Vaccine Development

Tick geographic expansion is speeding up worldwide, including for species that affect human wealth or economic activities, such as I. scapularis [126], H. longicornis [127] and R. (B.) microplus [128][129]. The losses caused by tick parasitism worldwide are estimated to be around USD 20 to USD 30 billion annually [130], a figure that will likely increase as ticks move to new areas due to global climate change. The presence of compatible hosts, climate, physical, and biotic factors is essential for tick establishment into new territories [104][129][131][132], where tick-borne pathogens can eventually also be introduced. For long-distance dispersion, human action as well as mammal and bird migration play a main role in such expansions [133][134]. Otherwise, for shorter distances, factors such as proximity to a tick-parasitized area, forest cover, and rivers are predicted to be favorable for tick spread [126].
Appropriate climate is one major restriction for tick establishment into new areas [131]. Consequently, the ability to exploit new geographic areas relies on the tick ecological plasticity. Species Distribution Modeling (SDM) is an in silico methodology used to analyze climatic niche expansion of I. ricinus, the most important tick vector of pathogens in Europe [131]. This work predicted that I. ricinus is expanding to about two times the current area due to an increase in human demographics and CO2 production. Otherwise, changes in temperature, rainfall, and moisture can shrink or increase tick geographic range, as a model predicted for the eastern paralysis tick Ixodes holocyclus (Neumann, 1899) in Australia [132] or for the bont tick Amblyomma hebraeum (Koch, 1884) in Zimbabwe [135]. Similarly, I. ricinus expansion would be affected by the balance between rising temperatures that extends the questing season and favor survival, and droughts that promote tick mortality [136]. Model predictions were used to forecast suitable habitat for R. (B.) microplus distribution in West Africa [137] and South America [129], where temperature was a key determinant for potential tick invasion.
The presence of ticks in new geographic areas imposes challenges to control strategies since new hosts will be susceptible to ticks and tick-borne pathogens [138]. This is a concern, especially for highly generalist ticks such as H. longicornis, already spread in North America and with the potential for expansion to new areas in Russia, equatorial Papua New Guinea, and Pacific Islands [129]. Another example includes the wild host reservoir for pathogens, e.g., B. burgdorferi transmitted by I. scapularis, which could increase the difficulty to eliminate Lyme disease in North America [126]. In these cases, the success of vaccination programs could be hindered by the presence of wild animals living near humans and livestock. Additionally, the invasion of R. (B.) microplus into new areas can disturb not only hosts but also native tick species, as is the case of R. (B.) decoloratus in Angola [128], Benin [138], and South Africa [139]. The recent expansion and establishment of R. (B.) microplus in these countries has already resulted in the partial displacement of R. (B.) decoloratus, affecting the stability of native and non-native pathogens.
Monitoring new emergence, as well as predicting the invasion of ticks into specific areas, is essential to guide strategies to develop a vaccine protecting against several tick species. For instance, hosts such as bovines or white-tailed deer would be immunized, respectively, against R. (B.) microplus and R. appendiculatus in Africa [128][139], and R. (B.) annulatus and R. (B.) microplus in America [140]. Universal vaccines would be extremely valuable for regions where the economy is heavily dependent on livestock activity.

References

  1. Boulanger, N.; Boyer, P.; Talagrand-Reboul, E.; Hansmann, Y. Ticks and tick-borne diseases. Med. Mal. Infect. 2019, 49, 87–97.
  2. Obaid, M.K.; Islam, N.; Alouffi, A.; Khan, A.Z.; da Silva Vaz, I., Jr.; Tanaka, T.; Ali, A. Acaricides Resistance in Ticks: Selection, Diagnosis, Mechanisms, and Mitigation. Front. Cell Infect. Microbiol. 2022, 12, 941831.
  3. Githaka, N.W.; Kanduma, E.G.; Wieland, B.; Darghouth, M.A.; Bishop, R.P. Acaricide resistance in livestock ticks infesting cattle in Africa: Current status and potential mitigation strategies. Curr. Res. Parasitol. Vector Borne Dis. 2022, 2, 100090.
  4. de la Fuente, J.; Estrada-Pena, A. Why New Vaccines for the Control of Ectoparasite Vectors Have Not Been Registered and Commercialized? Vaccines 2019, 7, 75.
  5. Muhanguzi, D.; Ndekezi, C.; Nkamwesiga, J.; Kalayou, S.; Ochwo, S.; Vuyani, M.; Kimuda, M.P. Anti-Tick Vaccines: Current Advances and Future Prospects. Methods Mol. Biol. 2022, 2411, 253–267.
  6. Sander, V.A.; Sanchez Lopez, E.F.; Mendoza Morales, L.; Ramos Duarte, V.A.; Corigliano, M.G.; Clemente, M. Use of Veterinary Vaccines for Livestock as a Strategy to Control Foodborne Parasitic Diseases. Front. Cell Infect. Microbiol. 2020, 10, 288.
  7. Choudhury, S.M.; Ma, X.; Dang, W.; Li, Y.; Zheng, H. Recent Development of Ruminant Vaccine Against Viral Diseases. Front. Vet. Sci. 2021, 8, 697194.
  8. Ellwanger, J.H.; Veiga, A.B.G.; Kaminski, V.L.; Valverde-Villegas, J.M.; Freitas, A.W.Q.; Chies, J.A.B. Control and prevention of infectious diseases from a One Health perspective. Genet. Mol. Biol. 2021, 44, e20200256.
  9. Stutzer, C.; Richards, S.A.; Ferreira, M.; Baron, S.; Maritz-Olivier, C. Metazoan Parasite Vaccines: Present Status and Future Prospects. Front. Cell Infect. Microbiol. 2018, 8, 67.
  10. Lewis, L.A.; Radulovic, Z.M.; Kim, T.K.; Porter, L.M.; Mulenga, A. Identification of 24h Ixodes scapularis immunogenic tick saliva proteins. Ticks Tick Borne Dis. 2015, 6, 424–434.
  11. Sun, T.; Wang, F.; Pan, W.; Wu, Q.; Wang, J.; Dai, J. An Immunosuppressive Tick Salivary Gland Protein DsCystatin Interferes With Toll-Like Receptor Signaling by Downregulating TRAF. Front. Immunol. 2018, 9, 1245.
  12. Wei, N.; Lin, Z.; Xu, Z.; Gong, H.; Zhang, H.; Zhou, Y.; Cao, J.; Li, G.; Zhou, J. Immunosuppressive effects of tick protein RHcyst-1 on murine bone marrow-derived dendritic cells. Parasites Vectors 2019, 12, 169.
  13. Coutinho, M.L.; Bizzarro, B.; Tirloni, L.; Berger, M.; Freire Oliveira, C.J.; Sa-Nunes, A.; Silva Vaz, I., Jr. Rhipicephalus microplus serpins interfere with host immune responses by specifically modulating mast cells and lymphocytes. Ticks Tick Borne Dis. 2020, 11, 101425.
  14. Sajiki, Y.; Konnai, S.; Ochi, A.; Okagawa, T.; Githaka, N.; Isezaki, M.; Yamada, S.; Ito, T.; Ando, S.; Kawabata, H.; et al. Immunosuppressive effects of sialostatin L1 and L2 isolated from the taiga tick Ixodes persulcatus Schulze. Ticks Tick Borne Dis. 2020, 11, 101332.
  15. Sajiki, Y.; Konnai, S.; Ikenaka, Y.; Gulay, K.C.M.; Kobayashi, A.; Parizi, L.F.; Joao, B.C.; Watari, K.; Fujisawa, S.; Okagawa, T.; et al. Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression. Sci. Rep. 2021, 11, 1063.
  16. Ali, A.; Zeb, I.; Alouffi, A.; Zahid, H.; Almutairi, M.M.; Ayed Alshammari, F.; Alrouji, M.; Termignoni, C.; Vaz, I.D.S., Jr.; Tanaka, T. Host Immune Responses to Salivary Components—A Critical Facet of Tick-Host Interactions. Front. Cell Infect. Microbiol. 2022, 12, 809052.
  17. Sajiki, Y.; Konnai, S.; Okagawa, T.; Maekawa, N.; Isezaki, M.; Yamada, S.; Ito, T.; Sato, K.; Kawabata, H.; Logullo, C.; et al. Suppressive effects of Ixodes persulcatus sialostatin L2 against Borrelia miyamotoi-stimulated immunity. Ticks Tick Borne Dis. 2022, 13, 101963.
  18. Penalver, E.; Arillo, A.; Delclos, X.; Peris, D.; Grimaldi, D.A.; Anderson, S.R.; Nascimbene, P.C.; Perez-de la Fuente, R. Parasitised feathered dinosaurs as revealed by Cretaceous amber assemblages. Nat. Commun. 2017, 8, 1924.
  19. Francischetti, I.M.; Sa-Nunes, A.; Mans, B.J.; Santos, I.M.; Ribeiro, J.M. The role of saliva in tick feeding. Front. Biosci. Landmark Ed. 2009, 14, 2051–2088.
  20. Nuttall, P.A. Tick saliva and its role in pathogen transmission. Wien. Klin. Wochenschr. 2019, 135, 165–176.
  21. Aounallah, H.; Bensaoud, C.; M’Ghirbi, Y.; Faria, F.; Chmelar, J.I.; Kotsyfakis, M. Tick Salivary Compounds for Targeted Immunomodulatory Therapy. Front. Immunol. 2020, 11, 583845.
  22. Narasimhan, S.; Kurokawa, C.; DeBlasio, M.; Matias, J.; Sajid, A.; Pal, U.; Lynn, G.; Fikrig, E. Acquired tick resistance: The trail is hot. Parasite Immunol. 2021, 43, e12808.
  23. Ribeiro, J.M. Role of saliva in tick/host interactions. Exp. Appl. Acarol. 1989, 7, 15–20.
  24. Rochlin, I.; Toledo, A. Emerging tick-borne pathogens of public health importance: A mini-review. J. Med. Microbiol. 2020, 69, 781–791.
  25. Pereira, D.F.S.; Ribeiro, H.S.; Goncalves, A.A.M.; da Silva, A.V.; Lair, D.F.; de Oliveira, D.S.; Boas, D.F.V.; Conrado, I.; Leite, J.C.; Barata, L.M.; et al. Rhipicephalus microplus: An overview of vaccine antigens against the cattle tick. Ticks Tick Borne Dis. 2022, 13, 101828.
  26. Rodriguez-Valle, M.; Taoufik, A.; Valdes, M.; Montero, C.; Ibrahin, H.; Hassan, S.M.; Jongejan, F.; de la Fuente, J. Efficacy of Rhipicephalus (Boophilus) microplus Bm86 against Hyalomma dromedarii and Amblyomma cajennense tick infestations in camels and cattle. Vaccine 2012, 30, 3453–3458.
  27. Antunes, S.; Domingos, A. Tick Vaccines and Concealed versus Exposed Antigens. Pathogens 2023, 12, 374.
  28. Fragoso, H.; Rad, P.H.; Ortiz, M.; Rodriguez, M.; Redondo, M.; Herrera, L.; de la Fuente, J. Protection against Boophilus annulatus infestations in cattle vaccinated with the B. microplus Bm86-containing vaccine Gavac. off. Vaccine 1998, 16, 1990–1992.
  29. Parizi, L.F.; Githaka, N.W.; Logullo, C.; Konnai, S.; Masuda, A.; Ohashi, K.; da Silva Vaz, I., Jr. The quest for a universal vaccine against ticks: Cross-immunity insights. Vet. J. 2012, 194, 158–165.
  30. Willadsen, P.; Riding, G.; McKenna, R.; Kemp, D.; Tellam, R.; Nielsen, J.; Gough, J. Immunologic control of a parasitic arthropod. Identification of a protective antigen from Boophilus microplus. J. Immunol. 1989, 143, 1346–1351.
  31. Johnston, L.A.; Kemp, D.; Pearson, R. Immunization of cattle against Boophilus microplus using extracts derived from adult female ticks: Effects of induced immunity on tick populations. Int. J. Parasitol. 1986, 16, 27–34.
  32. Willadsen, P.; Bird, P.; Cobon, G.S.; Hungerford, J. Commercialisation of a recombinant vaccine against Boophilus microplus. Parasitology 1995, 110, S43–S50.
  33. Canales, M.; Enriquez, A.; Ramos, E.; Cabrera, D.; Dandie, H.; Soto, A.; Falcon, V.; Rodriguez, M.; de la Fuente, J. Large-scale production in Pichia pastoris of the recombinant vaccine Gavac against cattle tick. Vaccine 1997, 15, 414–422.
  34. Tabor, A.E. A Review of Australian Tick Vaccine Research. Vaccines 2021, 9, 1030.
  35. de la Fuente, J.; Rodriguez, M.; Montero, C.; Redondo, M.; Garcia-Garcia, J.C.; Mendez, L.; Serrano, E.; Valdes, M.; Enriquez, A.; Canales, M.; et al. Vaccination against ticks (Boophilus spp.): The experience with the Bm86-based vaccine Gavac (TM). Genet. Anal. 1999, 15, 143–148.
  36. Kumar, B.; Murugan, K.; Ray, D.D.; Ghosh, S. Efficacy of rBm86 against Rhipicephalus (Boophilus) microplus (IVRI-I line) and Hyalomma anatolicum anatolicum (IVRI-II line) infestations on bovine calves. Parasitol. Res. 2012, 111, 629–635.
  37. Manzano-Roman, R.; Diaz-Martin, V.; Oleaga, A.; Perez-Sanchez, R. Identification of protective linear B-cell epitopes on the subolesin/akirin orthologues of Ornithodoros spp. soft ticks. Vaccine 2015, 33, 1046–1055.
  38. Kumar, B.; Manjunathachar, H.V.; Nagar, G.; Ravikumar, G.; de la Fuente, J.; Saravanan, B.C.; Ghosh, S. Functional characterization of candidate antigens of Hyalomma anatolicum and evaluation of its cross-protective efficacy against Rhipicephalus microplus. Vaccine 2017, 35, 5682–5692.
  39. Kasaija, P.D.; Contreras, M.; Kabi, F.; Mugerwa, S.; de la Fuente, J. Vaccination with Recombinant Subolesin Antigens Provides Cross-Tick Species Protection in Bos indicus and Crossbred Cattle in Uganda. Vaccines 2020, 8, 319.
  40. Hassan, I.A.; Wang, Y.; Zhou, Y.; Cao, J.; Zhang, H.; Zhou, J. Cross protection induced by combined Subolesin-based DNA and protein immunizations against adult Haemaphysalis longicornis. Vaccine 2020, 38, 907–915.
  41. Kasaija, P.D.; Contreras, M.; Kabi, F.; Mugerwa, S.; Garrido, J.M.; Gortazar, C.; de la Fuente, J. Oral vaccine formulation combining tick Subolesin with heat inactivated mycobacteria provides control of cross-species cattle tick infestations. Vaccine 2022, 40, 4564–4573.
  42. Sabadin, G.A.; Parizi, L.F.; Kiio, I.; Xavier, M.A.; da Silva Matos, R.; Camargo-Mathias, M.I.; Githaka, N.W.; Nene, V.; da Silva Vaz Jr, I. Effect of recombinant glutathione S-transferase as vaccine antigen against Rhipicephalus appendiculatus and Rhipicephalus sanguineus infestation. Vaccine 2017, 35, 6649–6656.
  43. Ndawula, C., Jr.; Sabadin, G.A.; Parizi, L.F.; da Silva Vaz, I., Jr. Constituting a glutathione S-transferase-cocktail vaccine against tick infestation. Vaccine 2019, 37, 1918–1927.
  44. Rodriguez-Mallon, A.; Encinosa, P.E.; Mendez-Perez, L.; Bello, Y.; Rodriguez Fernandez, R.; Garay, H.; Cabrales, A.; Mendez, L.; Borroto, C.; Estrada, M.P. High efficacy of a 20 amino acid peptide of the acidic ribosomal protein P0 against the cattle tick, Rhipicephalus microplus. Ticks Tick Borne Dis. 2015, 6, 530–537.
  45. Rodriguez-Mallon, A.; Encinosa Guzman, P.E.; Bello Soto, Y.; Rosales Perdomo, K.; Montero Espinosa, C.; Vargas, M.; Estrada Garcia, M.P. A chemical conjugate of the tick P0 peptide is efficacious against Amblyomma mixtum. Transbound. Emerg. Dis. 2020, 67, 175–177.
  46. Evora, P.M.; Sanches, G.S.; Guerrero, F.D.; Leon, A.P.; Bechara, G.H. Immunogenic potential of Rhipicephalus (Boophilus) microplus aquaporin 1 against Rhipicephalus sanguineus in domestic dogs. Rev. Bras. Parasitol. Vet. 2017, 26, 60–66.
  47. Perez-Sanchez, R.; Manzano-Roman, R.; Obolo-Mvoulouga, P.; Oleaga, A. Function-guided selection of midgut antigens from Ornithodoros erraticus ticks and an evaluation of their protective efficacy in rabbits. Vet. Parasitol. 2019, 272, 1–12.
  48. Githaka, N.W.; Konnai, S.; Isezaki, M.; Goto, S.; Xavier, M.A.; Fujisawa, S.; Yamada, S.; Okagawa, T.; Maekawa, N.; Logullo, C.; et al. Identification and functional analysis of ferritin 2 from the Taiga tick Ixodes persulcatus Schulze. Ticks Tick Borne Dis. 2020, 11, 101547.
  49. Parizi, L.F.; Rangel, C.K.; Sabadin, G.A.; Saggin, B.F.; Kiio, I.; Xavier, M.A.; da Silva Matos, R.; Camargo-Mathias, M.I.; Seixas, A.; Konnai, S.; et al. Rhipicephalus microplus cystatin as a potential cross-protective tick vaccine against Rhipicephalus appendiculatus. Ticks Tick Borne Dis. 2020, 11, 101378.
  50. Perez-Sanchez, R.; Manzano-Roman, R.; Obolo-Mvoulouga, P.; Oleaga, A. In silico selection of functionally important proteins from the mialome of Ornithodoros erraticus ticks and assessment of their protective efficacy as vaccine targets. Parasites Vectors 2019, 12, 508.
  51. Obolo-Mvoulouga, P.; Oleaga, A.; Manzano-Roman, R.; Perez-Sanchez, R. Evaluation of the protective efficacy of Ornithodoros moubata midgut membrane antigens selected using omics and in silico prediction algorithms. Ticks Tick Borne Dis. 2018, 9, 1158–1172.
  52. de Vos, S.; Zeinstra, L.; Taoufik, O.; Willadsen, P.; Jongejan, F. Evidence for the utility of the Bm86 antigen from Boophilus microplus in vaccination against other tick species. Exp. Appl. Acarol. 2001, 25, 245–261.
  53. Kumar, B.; Azhahianambi, P.; Ray, D.D.; Chaudhuri, P.; De La Fuente, J.; Kumar, R.; Ghosh, S. Comparative efficacy of rHaa86 and rBm86 against Hyalomma anatolicum anatolicum and Rhipicephalus (Boophilus) microplus. Parasite Immunol. 2012, 34, 297–301.
  54. Galai, Y.; Canales, M.; Ben Said, M.; Gharbi, M.; Mhadhbi, M.; Jedidi, M.; de La Fuente, J.; Darghouth, M.A. Efficacy of Hyalomma scupense (Hd86) antigen against Hyalomma excavatum and H. scupense tick infestations in cattle. Vaccine 2012, 30, 7084–7089.
  55. Ben Said, M.; Galai, Y.; Mhadhbi, M.; Jedidi, M.; de la Fuente, J.; Darghouth, M.A. Molecular characterization of Bm86 gene orthologs from Hyalomma excavatum, Hyalomma dromedarii and Hyalomma marginatum marginatum and comparison with a vaccine candidate from Hyalomma scupense. Vet. Parasitol. 2012, 190, 230–240.
  56. De La Fuente, J.; Rodríguez, M.; García-García, J.C. Immunological control of ticks through vaccination with Boophilus microplus gut antigens. Ann. N. Y. Acad. Sci. 2000, 916, 617–621.
  57. Ben Said, M.; Galai, Y.; Ben Ahmed, M.; Gharbi, M.; de la Fuente, J.; Jedidi, M.; Darghouth, M.A. Hd86 mRNA expression profile in Hyalomma scupense life stages, could it contribute to explain anti-tick vaccine effect discrepancy between adult and immature instars? Vet. Parasitol. 2013, 198, 258–263.
  58. Popara, M.; Villar, M.; Mateos-Hernandez, L.; de Mera, I.G.; Marina, A.; del Valle, M.; Almazan, C.; Domingos, A.; de la Fuente, J. Lesser protein degradation machinery correlates with higher BM86 tick vaccine efficacy in Rhipicephalus annulatus when compared to Rhipicephalus microplus. Vaccine 2013, 31, 4728–4735.
  59. Miller, R.; Estrada-Pena, A.; Almazan, C.; Allen, A.; Jory, L.; Yeater, K.; Messenger, M.; Ellis, D.; Perez de Leon, A.A. Exploring the use of an anti-tick vaccine as a tool for the integrated eradication of the cattle fever tick, Rhipicephalus (Boophilus) annulatus. Vaccine 2012, 30, 5682–5687.
  60. Arocho Rosario, C.M.; Miller, R.J.; Klafke, G.M.; Coates, C.; Grant, W.E.; Samenuk, G.; Yeater, K.; Tidwell, J.; Bach, S.; Perez de Leon, A.A.; et al. Interaction between anti-tick vaccine and a macrocyclic lactone improves acaricidal efficacy against Rhipicephalus (Boophilus) microplus (Canestrini) (Acari: Ixodidae) in experimentally infested cattle. Vaccine 2022, 40, 6795–6801.
  61. de la Fuente, J.; Maritz-Olivier, C.; Naranjo, V.; Ayoubi, P.; Nijhof, A.M.; Almazan, C.; Canales, M.; Perez de la Lastra, J.M.; Galindo, R.C.; Blouin, E.F.; et al. Evidence of the role of tick subolesin in gene expression. BMC Genom. 2008, 9, 372.
  62. Goto, A.; Matsushita, K.; Gesellchen, V.; El Chamy, L.; Kuttenkeuler, D.; Takeuchi, O.; Hoffmann, J.A.; Akira, S.; Boutros, M.; Reichhart, J.M. Akirins are highly conserved nuclear proteins required for NF-kappaB-dependent gene expression in drosophila and mice. Nat. Immunol. 2008, 9, 97–104.
  63. Galindo, R.C.; Doncel-Perez, E.; Zivkovic, Z.; Naranjo, V.; Gortazar, C.; Mangold, A.J.; Martin-Hernando, M.P.; Kocan, K.M.; de la Fuente, J. Tick subolesin is an ortholog of the akirins described in insects and vertebrates. Dev. Comp. Immunol. 2009, 33, 612–617.
  64. Nowak, S.J.; Aihara, H.; Gonzalez, K.; Nibu, Y.; Baylies, M.K. Akirin links twist-regulated transcription with the Brahma chromatin remodeling complex during embryogenesis. PLoS Genet. 2012, 8, e1002547.
  65. Carreon, D.; de la Lastra, J.M.; Almazan, C.; Canales, M.; Ruiz-Fons, F.; Boadella, M.; Moreno-Cid, J.A.; Villar, M.; Gortazar, C.; Reglero, M.; et al. Vaccination with BM86, subolesin and akirin protective antigens for the control of tick infestations in white tailed deer and red deer. Vaccine 2012, 30, 273–279.
  66. Contreras, M.; San Jose, C.; Estrada-Pena, A.; Talavera, V.; Rayas, E.; Isabel Leon, C.; Luis Nunez, J.; Garcia Fernandez de Mera, I.; de la Fuente, J. Control of tick infestations in wild roe deer (Capreolus capreolus) vaccinated with the Q38 Subolesin/Akirin chimera. Vaccine 2020, 38, 6450–6454.
  67. Moreno-Cid, J.A.; Perez de la Lastra, J.M.; Villar, M.; Jimenez, M.; Pinal, R.; Estrada-Pena, A.; Molina, R.; Lucientes, J.; Gortazar, C.; de la Fuente, J.; et al. Control of multiple arthropod vector infestations with subolesin/akirin vaccines. Vaccine 2013, 31, 1187–1196.
  68. Contreras, M.; de la Fuente, J. Control of Ixodes ricinus and Dermacentor reticulatus tick infestations in rabbits vaccinated with the Q38 Subolesin/Akirin chimera. Vaccine 2016, 34, 3010–3013.
  69. Manzano-Roman, R.; Encinas-Grandes, A.; Perez-Sanchez, R. Antigens from the midgut membranes of Ornithodoros erraticus induce lethal anti-tick immune responses in pigs and mice. Vet. Parasitol. 2006, 135, 65–79.
  70. Atanasova, M.; Dimitrov, I.; Doytchinov, I. T-cell epitope prediction by sequence-based methods and molecular docking of proteins from Boophilus microplus. Pharmacia 2017, 64, 3.
  71. Contreras, M.; Kasaija, P.D.; Kabi, F.; Mugerwa, S.; De la Fuente, J. The Correlation between Subolesin-Reactive Epitopes and Vaccine Efficacy. Vaccines 2022, 10, 1327.
  72. Lagunes, R.; Dominguez-Garcia, D.; Quiroz, H.; Martinez-Velazquez, M.; Rosario-Cruz, R. Potential effects on Rhipicephalus microplus tick larvae fed on calves immunized with a Subolesin peptide predicted by epitope analysis. Trop. Biomed. 2016, 33, 726–738.
  73. Lagunes-Quintanilla, R.; de la Cruz-Hernandez, N.I.; Ramirez-Guillen, P.N.; Merino-Charrez, J.O. Decrease in the cattle tick Rhipicephalus microplus biological parameters using anti-subolesin peptide antibodies by artificial capillary feeding. Trop. Biomed. 2018, 35, 492–500.
  74. Mendoza-Martinez, N.; Alonso-Diaz, M.A.; Merino, O.; Fernandez-Salas, A.; Lagunes-Quintanilla, R. Protective efficacy of the peptide Subolesin antigen against the cattle tick Rhipicephalus microplus under natural infestation. Vet. Parasitol. 2021, 299, 109577.
  75. Agianian, B.; Tucker, P.A.; Schouten, A.; Leonard, K.; Bullard, B.; Gros, P. Structure of a Drosophila sigma class glutathione S-transferase reveals a novel active site topography suited for lipid peroxidation products. J. Mol. Biol. 2003, 326, 151–165.
  76. Parizi, L.F.; Reck, J., Jr.; Oldiges, D.P.; Guizzo, M.G.; Seixas, A.; Logullo, C.; de Oliveira, P.L.; Termignoni, C.; Martins, J.R.; Vaz Ida, S., Jr. Multi-antigenic vaccine against the cattle tick Rhipicephalus (Boophilus) microplus: A field evaluation. Vaccine 2012, 30, 6912–6917.
  77. Rodriguez-Mallon, A.; Fernandez, E.; Encinosa, P.E.; Bello, Y.; Mendez-Perez, L.; Ruiz, L.C.; Perez, D.; Gonzalez, M.; Garay, H.; Reyes, O.; et al. A novel tick antigen shows high vaccine efficacy against the dog tick, Rhipicephalus sanguineus. Vaccine 2012, 30, 1782–1789.
  78. Rodriguez Mallon, A.; Javier Gonzalez, L.; Encinosa Guzman, P.E.; Bechara, G.H.; Sanches, G.S.; Pousa, S.; Cabrera, G.; Cabrales, A.; Garay, H.; Mejias, R.; et al. Functional and mass spectrometric evaluation of an anti-tick antigen based on the P0 peptide conjugated to Bm86 protein. Pathogens 2020, 9, 513.
  79. Terkawi, M.A.; Jia, H.; Gabriel, A.; Goo, Y.K.; Nishikawa, Y.; Yokoyama, N.; Igarashi, I.; Fujisaki, K.; Xuan, X. A shared antigen among Babesia species: Ribosomal phosphoprotein P0 as a universal babesial vaccine candidate. Parasitol. Res. 2007, 102, 35–40.
  80. Contreras, M.; Villar, M.; de la Fuente, J. A Vaccinomics approach for the identification of tick protective antigens for the control of Ixodes ricinus and Dermacentor reticulatus infestations in companion animals. Front. Physiol. 2019, 10, 977.
  81. Neelakanta, G.; Sultana, H. Transmission-Blocking Vaccines: Focus on Anti-Vector Vaccines against Tick-Borne Diseases. Arch. Immunol. Ther. Exp. 2015, 63, 169–179.
  82. Rego, R.O.M.; Trentelman, J.J.A.; Anguita, J.; Nijhof, A.M.; Sprong, H.; Klempa, B.; Hajdusek, O.; Tomas-Cortazar, J.; Azagi, T.; Strnad, M.; et al. Counterattacking the tick bite: Towards a rational design of anti-tick vaccines targeting pathogen transmission. Parasites Vectors 2019, 12, 229.
  83. Narasimhan, S.; Schuijt, T.J.; Abraham, N.M.; Rajeevan, N.; Coumou, J.; Graham, M.; Robson, A.; Wu, M.J.; Daffre, S.; Hovius, J.W.; et al. Modulation of the tick gut milieu by a secreted tick protein favors Borrelia burgdorferi colonization. Nat. Commun. 2017, 8, 184.
  84. Trimnell, A.R.; Davies, G.M.; Lissina, O.; Hails, R.S.; Nuttall, P.A. A cross-reactive tick cement antigen is a candidate broad-spectrum tick vaccine. Vaccine 2005, 23, 4329–4341.
  85. Labuda, M.; Trimnell, A.R.; Lickova, M.; Kazimirova, M.; Davies, G.M.; Lissina, O.; Hails, R.S.; Nuttall, P.A. An antivector vaccine protects against a lethal vector-borne pathogen. PLoS Pathog. 2006, 2, e27.
  86. Abraham, N.M.; Liu, L.; Jutras, B.L.; Yadav, A.K.; Narasimhan, S.; Gopalakrishnan, V.; Ansari, J.M.; Jefferson, K.K.; Cava, F.; Jacobs-Wagner, C.; et al. Pathogen-mediated manipulation of arthropod microbiota to promote infection. Proc. Natl. Acad. Sci. USA 2017, 114, E781–E790.
  87. Koci, J.; Bista, S.; Chirania, P.; Yang, X.; Kitsou, C.; Rana, V.S.; Yas, O.B.; Sonenshine, D.E.; Pal, U. Antibodies against EGF-like domains in Ixodes scapularis BM86 orthologs impact tick feeding and survival of Borrelia burgdorferi. Sci. Rep. 2021, 11, 6095.
  88. Almazan, C.; Moreno-Cantu, O.; Moreno-Cid, J.A.; Galindo, R.C.; Canales, M.; Villar, M.; de la Fuente, J. Control of tick infestations in cattle vaccinated with bacterial membranes containing surface-exposed tick protective antigens. Vaccine 2012, 30, 265–272.
  89. Torina, A.; Moreno-Cid, J.A.; Blanda, V.; Fernandez de Mera, I.G.; de la Lastra, J.M.; Scimeca, S.; Blanda, M.; Scariano, M.E.; Brigano, S.; Disclafani, R.; et al. Control of tick infestations and pathogen prevalence in cattle and sheep farms vaccinated with the recombinant Subolesin-Major Surface Protein 1a chimeric antigen. Parasites Vectors 2014, 7, 10.
  90. de la Fuente, J.; Moreno-Cid, J.A.; Galindo, R.C.; Almazan, C.; Kocan, K.M.; Merino, O.; Perez de la Lastra, J.M.; Estrada-Pena, A.; Blouin, E.F. Subolesin/Akirin vaccines for the control of arthropod vectors and vectorborne pathogens. Transbound. Emerg. Dis. 2013, 60, 172–178.
  91. Olds, C.L.; Mwaura, S.; Odongo, D.O.; Scoles, G.A.; Bishop, R.; Daubenberger, C. Induction of humoral immune response to multiple recombinant Rhipicephalus appendiculatus antigens and their effect on tick feeding success and pathogen transmission. Parasites Vectors 2016, 9, 484.
  92. Contreras, M.; Alberdi, P.; Fernandez De Mera, I.G.; Krull, C.; Nijhof, A.; Villar, M.; De La Fuente, J. Vaccinomics approach to the identification of candidate protective antigens for the control of tick vector infestations and Anaplasma phagocytophilum infection. Front. Cell Infect. Microbiol. 2017, 7, 360.
  93. Oldiges, D.P.; Laughery, J.M.; Tagliari, N.J.; Leite Filho, R.V.; Davis, W.C.; da Silva Vaz Jr, I.; Termignoni, C.; Knowles, D.P.; Suarez, C.E. Transfected Babesia bovis expressing a tick GST as a live vector vaccine. PLoS Negl. Trop. Dis. 2016, 10, e0005152.
  94. Shakya, M.; Kumar, B.; Nagar, G.; de la Fuente, J.; Ghosh, S. Subolesin: A candidate vaccine antigen for the control of cattle tick infestations in Indian situation. Vaccine 2014, 32, 3488–3494.
  95. Ali, A.; Ahmad, S.; de Albuquerque, P.M.M.; Kamil, A.; Alshammari, F.A.; Alouffi, A.; da Silva Vaz, I., Jr. Prediction of Novel Drug Targets and Vaccine Candidates against Human Lice (Insecta), Acari (Arachnida), and Their Associated Pathogens. Vaccines 2021, 10, 8.
  96. Cunha, R.C.; Andreotti, R.; Garcia, M.V.; Aguirre Ade, A.; Leitão, A. Calculation of the efficacy of vaccines against tick infestations on cattle. Rev. Bras. Parasitol. Vet. 2013, 22, 571–578.
  97. Aguirre Ade, A.; Lobo, F.P.; Cunha, R.C.; Garcia, M.V.; Andreotti, R. Design of the ATAQ peptide and its evaluation as an immunogen to develop a Rhipicephalus vaccine. Vet. Parasitol. 2016, 221, 30–38.
  98. Hue, T.; Petermann, J.; Bonnefond, R.; Mermoud, I.; Rantoen, D.; Vuocolo, T. Experimental efficacy of a vaccine against Rhipicephalus australis. Exp. Appl. Acarol. 2017, 73, 245–256.
  99. Martins, T.F.; Barbieri, A.R.; Costa, F.B.; Terassini, F.A.; Camargo, L.M.; Peterka, C.R.; de Pacheco, C.R.; Dias, R.A.; Nunes, P.H.; Marcili, A.; et al. Geographical distribution of Amblyomma cajennense (sensu lato) ticks (Parasitiformes: Ixodidae) in Brazil, with description of the nymph of A. cajennense (sensu stricto). Parasites Vectors 2016, 9, 186.
  100. Coimbra-Dores, M.J.; Nunes, T.; Dias, D.; Rosa, F. Rhipicephalus sanguineus (Acari: Ixodidae) species complex: Morphometric and ultrastructural analyses. Exp. Appl. Acarol. 2016, 70, 455–468.
  101. Ali, A.; Parizi, L.F.; Ferreira, B.R.; da Silva Vaz, I. A revision of two distinct species of Rhipicephalus: R. microplus and R. australis. Cienc. Rural. 2017, 46, 1240–1248.
  102. Costa, G.C.A.; Ribeiro, I.C.T.; Melo-Junior, O.; Gontijo, N.F.; Sant’Anna, M.R.V.; Pereira, M.H.; Pessoa, G.C.D.; Koerich, L.B.; Oliveira, F.; Valenzuela, J.G.; et al. Amblyomma sculptum Salivary Protease Inhibitors as Potential Anti-Tick Vaccines. Front. Immunol. 2020, 11, 611104.
  103. Garcia-Garcia, J.C.; Gonzalez, I.L.; Gonzalez, D.M.; Valdes, M.; Mendez, L.; Lamberti, J.; D’Agostino, B.; Citroni, D.; Fragoso, H.; Ortiz, M.; et al. Sequence variations in the Boophilus microplus Bm86 locus and implications for immunoprotection in cattle vaccinated with this antigen. Exp. Appl. Acarol. 1999, 23, 883–895.
  104. Estrada-Pena, A.; Mallon, A.R.; Bermudez, S.; de la Fuente, J.; Domingos, A.; Garcia, M.P.E.; Labruna, M.B.; Merino, O.; Mosqueda, J.; Nava, S.; et al. One Health Approach to Identify Research Needs on Rhipicephalus microplus Ticks in the Americas. Pathogens 2022, 11, 1180.
  105. de la Fuente, J.; Almazan, C.; Blas-Machado, U.; Naranjo, V.; Mangold, A.J.; Blouin, E.F.; Gortazar, C.; Kocan, K.M. The tick protective antigen, 4D8, is a conserved protein involved in modulation of tick blood ingestion and reproduction. Vaccine 2006, 24, 4082–4095.
  106. Zeb, I.; Almutairi, M.M.; Aloufi, A.; Islam, N.; Parizi, L.F.; Safi, S.Z.; Tanaka, T.; da Silva Vaz, I.; Ali, A. Low genetic polymorphism in the immunogenic sequences of Rhipicephalus microplus clade C. Vaccines 2022, 10, 1909.
  107. Parthasarathi, B.C.; Kumar, B.; Ghosh, S. Current status and future prospects of multi-antigen tick vaccine. J. Vector Borne Dis. 2021, 58, 183–192.
  108. Tirloni, L.; Reck, J.; Terra, R.M.; Martins, J.R.; Mulenga, A.; Sherman, N.E.; Fox, J.W.; Yates, J.R., 3rd; Termignoni, C.; Pinto, A.F.; et al. Proteomic analysis of cattle tick Rhipicephalus (Boophilus) microplus saliva: A comparison between partially and fully engorged females. PLoS ONE 2014, 9, e94831.
  109. Tirloni, L.; Islam, M.S.; Kim, T.K.; Diedrich, J.K.; Yates, J.R., 3rd; Pinto, A.F.; Mulenga, A.; You, M.J.; Da Silva Vaz, I., Jr. Saliva from nymph and adult females of Haemaphysalis longicornis: A proteomic study. Parasites Vectors 2015, 8, 338.
  110. Kim, T.K.; Tirloni, L.; Pinto, A.F.; Moresco, J.; Yates, J.R., 3rd; da Silva Vaz, I., Jr.; Mulenga, A. Ixodes scapularis Tick Saliva Proteins Sequentially Secreted Every 24 h during Blood Feeding. PLoS Negl. Trop. Dis. 2016, 10, e0004323.
  111. Tirloni, L.; Kim, T.K.; Pinto, A.F.M.; Yates, J.R., 3rd; da Silva Vaz, I., Jr.; Mulenga, A. Tick-Host Range Adaptation: Changes in Protein Profiles in Unfed Adult Ixodes scapularis and Amblyomma americanum Saliva Stimulated to Feed on Different Hosts. Front. Cell Infect. Microbiol. 2017, 7, 517.
  112. Contreras, M.; Kasaija, P.D.; Merino, O.; de la Cruz-Hernandez, N.I.; Gortazar, C.; de la Fuente, J. Oral vaccination with a formulation combining Rhipicephalus microplus subolesin with heat inactivated Mycobacterium bovis reduces tick infestations in cattle. Front. Cell Infect. Microbiol. 2019, 9, 45.
  113. Ndekezi, C.; Nkamwesiga, J.; Ochwo, S.; Kimuda, M.P.; Mwiine, F.N.; Tweyongyere, R.; Amanyire, W.; Muhanguzi, D. Identification of Ixodid tick-specific aquaporin-1 potential anti-tick vaccine epitopes: An in-silico analysis. Front. Bioeng. Biotechnol. 2019, 7, 236.
  114. Ndawula, C., Jr.; Amaral Xavier, M.; Villavicencio, B.; Cortez Lopes, F.; Juliano, M.A.; Parizi, L.F.; Verli, H.; da Silva Vaz, I., Jr.; Ligabue-Braun, R. Prediction, mapping and validation of tick glutathione S-transferase B-cell epitopes. Ticks Tick Borne Dis. 2020, 11, 101445.
  115. Couto, J.; Seixas, G.; Stutzer, C.; Olivier, N.A.; Maritz-Olivier, C.; Antunes, S.; Domingos, A. Probing the Rhipicephalus bursa sialomes in potential anti-tick vaccine candidates: A reverse vaccinology approach. Biomedicines 2021, 9, 363.
  116. de la Fuente, J.; Kopacek, P.; Lew-Tabor, A.; Maritz-Olivier, C. Strategies for new and improved vaccines against ticks and tick-borne diseases. Parasite Immunol. 2016, 38, 754–769.
  117. Bonam, S.R.; Partidos, C.D.; Halmuthur, S.K.M.; Muller, S. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol. Sci. 2017, 38, 771–793.
  118. Pan, Y.; Qi, Y.; Shao, N.; Tadle, A.C.; Huang, Y. Amino-modified polymer nanoparticles as adjuvants to activate the complement system and to improve vaccine efficacy in vivo. Biomacromolecules 2019, 20, 3575–3583.
  119. Petermann, J.; Bonnefond, R.; Mermoud, I.; Rantoen, D.; Meynard, L.; Munro, C.; Lua, L.H.L.; Hue, T. Evaluation of three adjuvants with respect to both adverse effects and the efficacy of antibody production to the Bm86 protein. Exp. Appl. Acarol. 2017, 72, 303–315.
  120. Mody, K.T.; Zhang, B.; Li, X.; Fletcher, N.L.; Akhter, D.T.; Jarrett, S.; Zhang, J.; Yu, C.; Thurecht, K.J.; Mahony, T.J.; et al. Characterization of the biodistribution of a silica vesicle nanovaccine carrying a Rhipicephalus (Boophilus) microplus protective antigen with in vivo live animal imaging. Front. Bioeng. Biotechnol. 2020, 8, 606652.
  121. VanBlargan, L.A.; Himansu, S.; Foreman, B.M.; Ebel, G.D.; Pierson, T.C.; Diamond, M.S. An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections. Cell. Rep. 2018, 25, 3382–3392.e3.
  122. Sajid, A.; Matias, J.; Arora, G.; Kurokawa, C.; DePonte, K.; Tang, X.; Lynn, G.; Wu, M.J.; Pal, U.; Strank, N.O.; et al. mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent. Sci. Transl. Med. 2021, 13, eabj9827.
  123. Shahrear, S.; Islam, A. Immunoinformatics guided modeling of CCHF_GN728, an mRNA-based universal vaccine against Crimean-Congo hemorrhagic fever virus. Comput. Biol. Med. 2021, 140, 105098.
  124. Bensaci, M.; Bhattacharya, D.; Clark, R.; Hu, L.T. Oral vaccination with vaccinia virus expressing the tick antigen subolesin inhibits tick feeding and transmission of Borrelia burgdorferi. Vaccine 2012, 30, 6040–6046.
  125. Oldiges, D.P.; Parizi, L.F.; Zimmer, K.R.; Lorenzini, D.M.; Seixas, A.; Masuda, A.; da Silva Vaz Jr, I.; Termignoni, C. A Rhipicephalus (Boophilus) microplus cathepsin with dual peptidase and antimicrobial activity. Int. J. Parasitol. 2012, 42, 635–645.
  126. Gardner, A.M.; Pawlikowski, N.C.; Hamer, S.A.; Hickling, G.J.; Miller, J.R.; Schotthoefer, A.M.; Tsao, J.I.; Allan, B.F. Landscape features predict the current and forecast the future geographic spread of Lyme disease. Proc. Biol. Sci. 2020, 287, 20202278.
  127. Raghavan, R.K.; Barker, S.C.; Cobos, M.E.; Barker, D.; Teo, E.J.M.; Foley, D.H.; Nakao, R.; Lawrence, K.; Heath, A.C.G.; Peterson, A.T. Potential spatial distribution of the newly introduced long-horned tick, Haemaphysalis longicornis in North America. Sci. Rep. 2019, 9, 498.
  128. Gomes, A.F.; Neves, L. Rhipicephalus microplus (Acarina, Ixodidae) in Angola: Evidence of its establishment and expansion. Exp. Appl. Acarol. 2018, 74, 117–122.
  129. Nava, S.; Gamietea, I.J.; Morel, N.; Guglielmone, A.A.; Estrada-Pena, A. Assessment of habitat suitability for the cattle tick Rhipicephalus (Boophilus) microplus in temperate areas. Res. Vet. Sci. 2022, 150, 10–21.
  130. Lew-Tabor, A.E.; Rodriguez Valle, M. A review of reverse vaccinology approaches for the development of vaccines against ticks and tick borne diseases. Ticks Tick Borne Dis. 2016, 7, 573–585.
  131. Porretta, D.; Mastrantonio, V.; Amendolia, S.; Gaiarsa, S.; Epis, S.; Genchi, C.; Bandi, C.; Otranto, D.; Urbanelli, S. Effects of global changes on the climatic niche of the tick Ixodes ricinus inferred by species distribution modelling. Parasites Vectors 2013, 6, 271.
  132. Teo, E.J.M.; Vial, M.N.; Hailu, S.; Kelava, S.; Zalucki, M.P.; Furlong, M.J.; Barker, D.; Barker, S.C. Climatic requirements of the eastern paralysis tick, Ixodes holocyclus, with a consideration of its possible geographic range up to Int. J. Parasitol. 2021, 51, 241–249.
  133. Cortinas, M.R.; Kitron, U. County-level surveillance of white-tailed deer infestation by Ixodes scapularis and Dermacentor albipictus (Acari: Ixodidae) along the Illinois River. J. Med. Entomol. 2006, 43, 810–819.
  134. Ogden, N.H.; Lindsay, L.R.; Hanincova, K.; Barker, I.K.; Bigras-Poulin, M.; Charron, D.F.; Heagy, A.; Francis, C.M.; O’Callaghan, C.J.; Schwartz, I.; et al. Role of migratory birds in introduction and range expansion of Ixodes scapularis ticks and of Borrelia burgdorferi and Anaplasma phagocytophilum in Canada. Appl. Environ. Microbiol. 2008, 74, 1780–1790.
  135. Tagwireyi, P.; Ndebele, M.; Chikurunhe, W. Climate change diminishes the potential habitat of the bont tick (Amblyomma hebraeum): Evidence from Mashonaland Central Province, Zimbabwe. Parasites Vectors 2022, 15, 237.
  136. Gray, J.; Kahl, O.; Zintl, A. What do we still need to know about Ixodes ricinus? Ticks Tick Borne Dis. 2021, 12, 101682.
  137. Zannou, O.M.; Da Re, D.; Ouedraogo, A.S.; Biguezoton, A.S.; Abatih, E.; Yao, K.P.; Farougou, S.; Lempereur, L.; Vanwambeke, S.O.; Saegerman, C. Modelling habitat suitability of the invasive tick Rhipicephalus microplus in West Africa. Transbound. Emerg. Dis. 2022, 69, 2938–2951.
  138. Ouedraogo, A.S.; Zannou, O.M.; Biguezoton, A.S.; Kouassi, P.Y.; Belem, A.; Farougou, S.; Oosthuizen, M.; Saegerman, C.; Lempereur, L. Cattle ticks and associated tick-borne pathogens in Burkina Faso and Benin: Apparent northern spread of Rhipicephalus microplus in Benin and first evidence of Theileria velifera and Theileria annulata. Ticks Tick Borne Dis. 2021, 12, 101733.
  139. Nyangiwe, N.; Harrison, A.; Horak, I.G. Displacement of Rhipicephalus decoloratus by Rhipicephalus microplus (Acari: Ixodidae) in the Eastern Cape Province, South Africa. Exp. Appl. Acarol. 2013, 61, 371–382.
  140. Estrada-Pena, A.; Carreon, D.; Almazan, C.; de la Fuente, J. Modeling the impact of climate and landscape on the efficacy of white tailed deer vaccination for cattle tick control in northeastern Mexico. PLoS ONE 2014, 9, e102905.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Parasitology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Luís Fernando Parizi
,
Naftaly Wang’ombe Githaka
,
Carlos Logullo
,
Jinlin Zhou
,
Misao Onuma
,
Carlos Termignoni
,
Itabajara da Silva Vaz
View Times: 197
Revisions: 2 times (View History)
Update Date: 03 Jul 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback